Transcription of Interleukin-8: How Altered Regulation Can Affect Cystic Fibrosis Lung Disease

Biomolecules. 2015 Jul 1;5(3):1386-98. doi: 10.3390/biom5031386.

Abstract

Interleukin-8 (IL-8) is a neutrophil chemokine that is encoded on the CXCL8 gene. Normally CXCL8 expression is repressed due to histone deacetylation, octamer-1 binding to the promoter and the inhibitory effect of nuclear factor-κB repressing factor (NRF). However, in response to a suitable stimulus, the human CXCL8 gene undergoes transcription due to its inducible promoter that is regulated by the transcription factors nuclear factor-κB (NF-κB), activating protein (AP-1), CAAT/enhancer-binding protein β (C/EBPβ, also known as NF-IL-6), C/EBP homologous protein (CHOP) and cAMP response element binding protein (CREB). CXCL8 mRNA is then stabilised by the activity of p38 mitogen-activated protein kinase (p38 MAPK). Cystic fibrosis (CF) lung disease is characterised by a neutrophil-dominated airway inflammatory response. A major factor contributing to the large number of neutrophils is the higher than normal levels of IL-8 that are present within the CF lung. Infection and inflammation, together with intrinsic alterations in CF airway cells are responsible for the abnormally high intrapulmonary levels of IL-8. Strategies to inhibit aberrantly high CXCL8 expression hold therapeutic potential for CF lung disease.

Keywords: cystic fibrosis; interleukin-8; lung.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / genetics*
  • Gene Expression Regulation* / drug effects
  • Humans
  • Interleukin-8 / genetics*
  • Lung / drug effects
  • Lung / metabolism
  • Molecular Targeted Therapy
  • Transcription, Genetic* / drug effects

Substances

  • Interleukin-8